Saturday, March 18, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

DHS Award for Biothreat Antibody Development

by Global Biodefense Staff
July 14, 2014

The DHS Directorate of Science and Technology, Chemical and Biological Defense Division has awarded a sole source contract to Silver Lake Research Corporation (SLRC) for continued development of threat agent specific monoclonal antibodies supporting development of rapid detection assays.

SLRC has produced a group of highly specific monoclonal antibodies for use in DHS and FEDGOV assays. DHS requires that SLRC continue and complete the work for the research, development and generation of hyper-specific monoclonal antibodies specific for bacterial and viral biothreat agents.

The overall objective is to develop and deploy highly specific and sensitive rapid first responder, clinical diagnostic, and biothreat detection assays capable of fulfilling the needs of multiple agencies and departments to support the national biodefense and preparedness mission. This requirement was originally awarded to Silver Lake Research Corporation (SLRC) on June 4, 2012 under DHS Long Range Broad Agency Announcement 11-03, with several continuation contracts since that time.

“Using an innovative and proprietary EAP Immunization methods, SLRC has overcome the technical problems associated with the work that has been performed thus far under the previous and current DHS contracts to overcome the probable “non-immunogenicity” of selected sequences, and ensure that the antibodies are designed to bind to the selected sequence in the context of the intact native protein,” states the announcement.

Previously completed results from SLRC showed that of the four Bacillus anthracis antigenic marker peptides used, all four produced specific MAbs which are now being characterized by DHS, U.S. Center for Disease Control (CDC), and other Federal Research Laboratories.

“This accomplishment marks the first successful attempt to employ cytokine mediated artificial host responses, coupled with bioinformatics driven recombinant antigens as a rational approach to generating highly specific antibodies to support the development of rapid detection assays for the national biodefense and preparedness mission,” states the announcement.

Tags: AnthraxAwardsBioinformaticsChemical DetectionDHS

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
Researcher holds a pipette
Biodetection

These Nanotech Bubbles Burst When They Detect Viruses in the Air

October 25, 2022
research team gathers in front of a window
CBRNE

UAMS Receives $3.4 Million to Study Radiation Injuries Caused by Nuclear Accidents and Bioterrorism

August 24, 2022
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy